Precious Cargo — Pregnancy as a Cardiovascular Stress Test
Case Presentation
Case A: “It Resolved After Delivery” (Age 32)
A 32-year-old woman experiences her first pregnancy. During the third trimester, her blood pressure begins to rise. She is diagnosed with gestational hypertension. Later in pregnancy, her glucose screening is abnormal, though she does not meet criteria for overt gestational diabetes.
She is reassured: “This happens in pregnancy. Everything should go back to normal after delivery.”
Her blood pressure and glucose normalize postpartum. At her 6-week follow-up, she is told no further evaluation is needed.
Case B: Years Later — A Different Clinic, the Same Biology (Age 45)
More than a decade later, the same woman presents for routine primary care. She feels generally well but reports:
- Gradual weight gain, especially around the abdomen
- Rising blood pressure over several visits
- Fatigue and reduced exercise tolerance
Her labs show:
- Fasting glucose and A1c drifting upward
- Mild hypertriglyceridemia
- LDL-C described as “acceptable”
Her pregnancy history is not discussed.
Flying Under the Radar
Pregnancy complications are often framed as temporary obstetric events, not early cardiovascular signals.
Several structural issues contribute:
- OB care and primary care operate in separate silos
- Postpartum follow-up focuses on short-term recovery
- Risk calculators ignore pregnancy history
- Women are often young when complications occur — masking lifetime risk
The result is a missed opportunity to recognize cardiometabolic vulnerability years before disease develops.
The 2026 ACC/AHA/NLA Dyslipidemia Guidelines introduce nuanced, risk-based guidance for lipid-lowering therapy (LLT) in pregnancy, significantly refining the previous approach of blanket statin avoidance:
General Population (Low ASCVD Risk): Stop statins 1–2 months before attempting pregnancy (COR I, LOE C-EO). This remains standard for women without established cardiovascular disease or familial hypercholesterolemia.
NEW Nuanced Guidance for High-Risk Groups: Women with familial hypercholesterolemia (FH), ASCVD, or very high risk may be reasonable to CONTINUE statin therapy during pregnancy following detailed shared decision-making (COR 2b, LOE C-LD). This marks a significant shift from the prior blanket prohibition and reflects emerging evidence that untreated hypercholesterolemia in pregnancy carries substantive maternal and fetal risks in select populations.
Homozygous FH (HoFH): Lipoprotein apheresis during pregnancy remains the standard for severe LDL-C elevation (COR 2a, LOE C-LD).
FDA and Pregnancy Category Evolution: In 2021, the FDA reclassified statins from absolute contraindication to individualized risk-benefit assessment, reflecting evolving preclinical and observational data. Comprehensive LLT safety data in pregnancy and lactation are now codified in Table 20 of the guideline.
Reproductive Risk Markers — NEW ASCVD Risk Enhancers: The 2026 guideline formally classifies six pregnancy-related conditions as ASCVD risk enhancers to be incorporated into all risk assessment and personalization strategies:
- Preeclampsia (including HELLP syndrome)
- Gestational diabetes
- Preterm delivery (<37 weeks)
- Early menopause (<40 years)
- Polycystic ovary syndrome (PCOS)
The Core Phenotype: Pregnancy as a Cardiovascular Stress Test
Pregnancy places extraordinary demands on vascular function, endothelial health, insulin sensitivity, and cardiac reserve.
In most women, the system adapts. In others, pregnancy unmasks underlying susceptibility that later reappears as:
- Chronic hypertension
- Type 2 diabetes
- Atherosclerotic cardiovascular disease (ASCVD)
- Heart failure with preserved ejection fraction (HFpEF)
A landmark study from the NIH All of Us research program (17,357 women across >50 U.S. health systems) found that hypertensive disorders of pregnancy were associated with a nearly 2-fold higher risk of premature cardiovascular disease (aHR 1.82) within the first decade postpartum. Critically, this elevated risk persisted even in women without any prepregnancy cardiometabolic conditions (aHR 2.06) — confirming that hypertensive disorders of pregnancy is an independent marker of cardiovascular vulnerability, not merely a reflection of pre-existing risk factors. The study enrolled one of the most diverse cohorts to date: 42% Hispanic/Latino, 16% Black or African American, and 35% with household income below $25,000. Findings were replicated in an independent health system (n=56,549) with consistent results.
Boyer TM, Barrett RB, Xiong C, et al. Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. Circulation. 2026;153:480–492.
Signals That Should Not Be Dismissed
| Pregnancy Complication | What It Signals | Long-Term Risk |
|---|---|---|
| Gestational hypertension | Early vascular dysfunction | Future chronic hypertension, accelerated atherosclerosis |
| Preeclampsia | Endothelial dysfunction, angiogenic imbalance | ~2× premature CVD risk (Boyer 2026); HFpEF |
| HELLP syndrome | Severe endothelial and hepatic stress | Highest cardiovascular risk trajectory |
| Gestational diabetes | Early insulin resistance | Future type 2 diabetes, metabolic syndrome |
| Impaired glucose tolerance | Subclinical insulin resistance | Triglyceride elevation, ApoB discordance |
Why This Matters for Women’s Heart Disease
Women with a history of pregnancy-related cardiometabolic complications:
- Develop cardiovascular disease earlier than peers — the Boyer 2026 study found premature CVD within a median of 4.6 years postpartum
- Face elevated risk even without prepregnancy risk factors (2-fold increased CVD risk in otherwise healthy women)
- Are more likely to develop HFpEF
- Often present with disease despite “normal” LDL-C
Yet these signals are rarely integrated into long-term risk assessment.
Projected trends for U.S. women:
• Hypertension: 48.6% (2020) → 59.1% (2050)
• Obesity: 43.9% → 61.2%
• Diabetes: 14.9% → 25.3%
• Childhood obesity: nearly 1 in 3 girls ages 2–19 projected to have obesity by 2050 (4 in 10 Black girls)
These projections reinforce why pregnancy complications — as early markers of cardiometabolic vulnerability — demand urgent, lifelong follow-up rather than reassurance alone.
• Women: 3.1% in-hospital STEMI mortality (vs. 2.6% for men)
• Women received fewer cardiovascular procedures despite similar complication rates
• Nontraditional risk factors (low income, kidney disease, non-tobacco drug use) were more strongly linked to death than traditional risk factors
This data is directly relevant to the pregnancy phenotype: young women with prior pregnancy complications who go on to develop premature ASCVD face higher mortality and receive less aggressive treatment than men — a compounded disparity. The failure to recognize pregnancy complications as cardiovascular red flags — and the absence of structured postpartum follow-up — may be a contributing factor to these worsening statistics in younger women.
Why Risk Calculators Fail This Phenotype
Traditional risk tools focus on 10-year risk, are dominated by age, ignore pregnancy history, and underestimate lifetime exposure. This phenotype remains invisible until disease is established.
From Pregnancy to HFpEF
Hypertensive disorders of pregnancy and metabolic dysfunction increase risk for heart failure with preserved ejection fraction (HFpEF), a form of heart failure that disproportionately affects women.
HFpEF risk can emerge within the first decade after pregnancy. Women with a history of preeclampsia/eclampsia have markedly increased risk of HFpEF hospitalization. The median time to HFpEF diagnosis is approximately 32 months (~2.7 years) after preeclampsia, highlighting early risk emergence.
HFpEF is biologically linked to:
- Microvascular and endothelial dysfunction
- Chronic inflammation
- Altered ventricular–vascular coupling
- Visceral adiposity and metabolic dysregulation
Because disease-modifying therapies for HFpEF are limited once structural remodeling is established, early recognition of this trajectory matters.
Beyond the Mother: Cardiovascular Risk in the Offspring
Pregnancy-related cardiometabolic complications affect not only the mother but also program long-term cardiovascular risk in offspring, beginning in childhood and persisting into adulthood.
| Maternal Condition | Offspring Risk Increase | Conditions at Higher Risk |
|---|---|---|
| Hypertensive disorders of pregnancy | ~23% increased rate of early-onset CVD | Hypertensive disease, myocardial infarction |
| Maternal diabetes/dysglycemia | ~29% increased rate of early-onset CVD | Heart failure, hypertensive disease, venous thromboembolism |
| Combined conditions | Highest long-term CV risk | Amplified risk across all categories |
Proposed mechanisms:
- Endothelial dysfunction and angiogenic imbalance
- Chronic inflammation and oxidative stress
- Alterations in the renin–angiotensin–aldosterone system
- Epigenetic programming (DNA methylation and microRNA dysregulation)
CardioAdvocate™ Checklist — Questions to Ask
How to phrase it: “I had blood pressure or blood sugar issues during pregnancy. I’d like to understand what that means for my heart health now.”
Deep Dive
This is a living section — a deeper exploration of the science behind this phenotype.
Pregnancy as a Cardiovascular Stress Test
Pregnancy unmasks susceptibility to endothelial dysfunction and insulin resistance. Hypertensive disorders of pregnancy and gestational dysglycemia are now recognized as cardiovascular risk enhancers, not isolated obstetric events. The 2019 ACC/AHA Prevention Guidelines explicitly include pregnancy complications as risk-enhancing factors.
In February 2026, Circulation’s Go Red for Women issue published the most diverse U.S. study to date on this question. Boyer et al. studied 17,357 women in the NIH All of Us cohort and found that hypertensive disorders of pregnancy carried a 1.82-fold increased risk of premature CVD (ischemic heart disease, heart failure, or stroke) within a median of 4.6 years postpartum. The risk was even stronger — 2.06-fold — among women who had no prepregnancy cardiometabolic conditions whatsoever (no hypertension, obesity, diabetes, hyperlipidemia, or CKD). This finding answers a fundamental question in the field: hypertensive disorders of pregnancy is not simply unmasking pre-existing risk — it independently accelerates cardiovascular aging.
Importantly, this cohort reflected the populations most affected: 42% Hispanic/Latino, 16% Black or African American, and 35% with household income below $25,000 — groups that bear a disproportionate burden of maternal morbidity yet have been historically underrepresented in cardiovascular research. Go Red for Women initiatives continue to prioritize these disparities.
Boyer TM, Barrett RB, Xiong C, et al. Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. Circulation. 2026;153:480–492.
Catov JM et al. Pregnancy complications and later-life cardiovascular disease. J Am Coll Cardiol. 2018.
Hypertensive Disorders of Pregnancy and Cardiovascular Disease Risk. Circulation. 2011;124:1606–1614.
From Pregnancy to HFpEF
Hypertensive disorders of pregnancy and metabolic dysfunction increase risk for heart failure with preserved ejection fraction (HFpEF), a form of heart failure that disproportionately affects women.
Importantly, HFpEF risk does not emerge decades later only — it often begins within the first decade after pregnancy.
Evidence shows:
- Women with a history of preeclampsia/eclampsia have a markedly increased risk of HFpEF hospitalization
- Median time to HFpEF diagnosis is approximately 32 months (~2.7 years) after preeclampsia, highlighting how early this risk may declare itself
- Risk persists and amplifies over time, particularly in the presence of hypertension, insulin resistance, and obesity
HFpEF is biologically linked to:
- Microvascular and endothelial dysfunction
- Chronic inflammation
- Altered ventricular–vascular coupling
- Visceral adiposity and metabolic dysregulation
Because disease-modifying therapies for HFpEF are limited once structural remodeling is established, early recognition of this trajectory matters.
Williams D, Stout MJ, Rosenbloom JI, et al. Preeclampsia Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2021.
Hansen AL, Søndergaard MM, Hlatky MA, et al. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women's Health Initiative. JAMA Netw Open. 2021.
Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2023.
The Transition to Metabolic Syndrome
Many women with pregnancy-related cardiometabolic complications develop metabolic syndrome within 10–15 years of delivery. This transition often occurs silently, masked by “normal” LDL-C and low short-term risk scores.
The key metabolic markers to track include:
- Triglyceride trends over time
- HDL-C trajectory (declining HDL-C is a red flag)
- Fasting glucose and A1c
- Blood pressure trajectories
- Waist circumference and visceral adiposity
Early identification of this trajectory may allow intervention before structural remodeling becomes irreversible.
Beyond the Mother: Cardiovascular Risk in the Offspring
Pregnancy-related cardiometabolic complications do not only affect the mother. Growing evidence shows they also program long-term cardiovascular risk in the offspring, beginning in childhood and persisting into adulthood.
Hypertensive disorders of pregnancy (HDP):
- Associated with a ~23% increased rate of early-onset cardiovascular disease in offspring
- Particularly elevated risks for:
- Hypertensive disease
- Myocardial infarction
- Risk observed from childhood through early adulthood
Maternal diabetes and dysglycemia:
- Associated with a ~29% increased rate of early-onset cardiovascular disease in offspring
- Risk observed with both gestational and pregestational diabetes
- Particularly strong associations with:
- Heart failure
- Hypertensive disease
- Venous thromboembolism
Combined maternal conditions amplify risk:
- Concomitant gestational hypertension and gestational diabetes confer the highest long-term cardiovascular risk in offspring
- Risk is further amplified when maternal cardiovascular disease is also present
Proposed mechanisms:
- Endothelial dysfunction and angiogenic imbalance
- Chronic inflammation and oxidative stress
- Alterations in the renin–angiotensin–aldosterone system
- Epigenetic programming (DNA methylation and microRNA dysregulation)
Huang C, Li J, Qin G, et al. Maternal Hypertensive Disorder of Pregnancy and Offspring Early-Onset Cardiovascular Disease in Childhood, Adolescence, and Young Adulthood. PLoS Med. 2021.
Taageby Nielsen S, Luo J, Tybjærg-Hansen A, et al. Preeclampsia, Gestational Hypertension, and Cardiovascular Disease Risk: A Genetic Epidemiological Study. Eur Heart J. 2025.
Yu Y, Arah OA, Liew Z, et al. Maternal Diabetes During Pregnancy and Early Onset of Cardiovascular Disease in Offspring: Population-Based Cohort Study With 40 Years of Follow-Up. BMJ. 2019.
Alejandra MH, Ricardo ET, Guadalupe DL. Crosstalk Between Hypertension and Diabetes: Focusing on Pregnancy and Offspring. A Systematic Review. Front Physiol. 2024.
Echouffo Tcheugui JB, Guan J, Fu L, Retnakaran R, Shah BR. Association of Concomitant Gestational Hypertensive Disorders and Gestational Diabetes With Cardiovascular Disease. JAMA Netw Open. 2022.
Svigkou A, Katsi V, Kordalis VG, Tsioufis K. The Molecular Basis of the Augmented Cardiovascular Risk in Offspring of Mothers With Hypertensive Disorders of Pregnancy. Int J Mol Sci. 2024.
Women-Specific Cardiovascular Conditions
While traditionally underrecognized, two cardiovascular conditions disproportionately affect women of reproductive age and warrant special attention in the context of pregnancy-related risk:
Spontaneous Coronary Artery Dissection (SCAD)
SCAD is a tear in the wall of a coronary artery that occurs in the absence of atherosclerosis. It is the leading cause of myocardial infarction in women under age 50 and disproportionately affects otherwise healthy, young women. Peripartum and postpartum SCAD — occurring during pregnancy or within months after delivery — represents a distinct and life-threatening phenotype.
Why this matters: Traditional risk calculators entirely miss SCAD risk because it is not atherosclerotic. Peripartum SCAD occurs in women without traditional CV risk factors and demands rapid recognition. Hayes SN et al. JACC 2018 established diagnostic criteria and highlighted the importance of angiography and advanced imaging. Women with SCAD should not undergo standard percutaneous coronary intervention; specialized management is required.
Coronary Microvascular Disease (CMD)
Coronary microvascular disease involves dysfunction of the tiny coronary vessels that feed the heart muscle — vessels too small to be visualized on standard angiography. Women account for a disproportionate share of CMD cases and present with angina despite angiographically “clean” coronary arteries. Pregnancy-related endothelial dysfunction may increase CMD risk.
Why this matters: CMD is frequently dismissed in women presenting with chest pain and normal coronaries, leading to prolonged diagnostic delay and psychological harm. Functional assessment (coronary flow reserve, index of microvascular resistance) and advanced imaging are needed for diagnosis. Bairey Merz CN et al. JACC 2017 provide diagnostic frameworks. Women with pregnancy-related endothelial dysfunction and persistent angina warrant assessment for CMD.
Both SCAD and CMD represent opportunities for heightened vigilance in women with pregnancy-related cardiometabolic complications. Recognition of these conditions expands the spectrum of cardiovascular risk beyond traditional atherosclerotic disease and reinforces the importance of individualized assessment.
Phenotype Cross-Links
The sister phenotype: midlife women with reassuring numbers and underestimated risk.
The downstream consequence of unrecognized metabolic risk in women.
Triglycerides, HDL decline, and ApoB discordance — where this trajectory leads.
When insulin resistance becomes the central driver.
When high HDL-C misleads and protection fails.
Seeing disease before symptoms.
The Bottom Line
Pregnancy complications are not footnotes.
They are early warnings — offering a rare window to identify and modify cardiovascular risk decades before events occur.
February 2026 Update: New evidence makes the case for postpartum cardiovascular vigilance more urgent than ever. Young adult MI deaths are rising again (Satish et al., JAHA 2026), with women bearing disproportionate mortality (3.1% vs. 2.6%) and receiving fewer procedures. The inaugural JACC Cardiovascular Statistics 2026 report (Wadhera et al.), analyzed by the Harvard Gazette, confirms that guideline-directed therapy implementation has stalled nationwide — meaning the women identified by pregnancy complications are even less likely to receive the follow-up they need. The lack of awareness and detection of these red flags during pregnancy, combined with the absence of structured long-term cardiovascular follow-up postpartum, may be directly contributing to these worsening outcomes in younger women.
Precious cargo deserves long-term protection — not reassurance alone.
